Vir Biotechnology, Inc. Quarterly Debt-to-equity in % from Q2 2020 to Q1 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Vir Biotechnology, Inc. quarterly Debt-to-equity history and growth rate from Q2 2020 to Q1 2023.
  • Vir Biotechnology, Inc. Debt-to-equity for the quarter ending March 31, 2023 was 32.3 %, a 21% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2023 32.3 -8.58 -21% Mar 31, 2023
Q4 2022 34.5 -10.4 -23.2% Dec 31, 2022
Q3 2022 34.8 -10.2 -22.6% Sep 30, 2022
Q2 2022 38.5 -0.51 -1.31% Jun 30, 2022
Q1 2022 40.9 +7.13 +21.1% Mar 31, 2022
Q4 2021 44.9 +23.2 +107% Dec 31, 2021
Q3 2021 45 +25.5 +131% Sep 30, 2021
Q2 2021 39 +5.87 +17.7% Jun 30, 2021
Q1 2021 33.7 Mar 31, 2021
Q4 2020 21.8 Dec 31, 2020
Q3 2020 19.5 Sep 30, 2020
Q2 2020 33.1 Jun 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.